Gastric carcinoma, being one of the most prevalent types of solid tumors, has emerged as the third leading cause of death worldwide. The symptoms of gastric cancer (GC) are typically complex, which makes early detection challenging. Immune checkpoint inhibition has become the new standard targeted therapy for advanced or metastatic GC. It is currently being explored in various combinations, both with and without chemotherapy, across multiple therapies in clinical trials. Immunotherapy can stimulate immune responses in GC patients, leading to the destruction of cancer cells. Compared with traditional therapies, immunotherapy has shown strong effectiveness with tolerable toxicity levels. Hence, this innovative approach to the treatment of advanced GC has gained popularity. In this review, we have outlined the recent advancements in immunotherapy for advanced GC, including immune checkpoint inhibitors, cancer vaccines, vascular endothelial growth factor-A inhibitors, and chimeric antigen receptor T-cell therapy. Our current emphasis is on examining the immunotherapies presently employed in clinical settings, addressing the existing challenges associated with these therapeutic approaches, and exploring promising strategies to overcome their limitations.
胃癌作为最常见的实体肿瘤之一，已成为全球第三大致死原因。胃癌症状通常较为复杂，这使得早期诊断颇具挑战性。免疫检查点抑制已成为晚期或转移性胃癌的新型标准靶向疗法，目前正通过临床试验探索其与化疗联合或非化疗联合的多种治疗方案。免疫疗法能够激发胃癌患者的免疫应答，从而实现对癌细胞的清除。与传统疗法相比，免疫疗法展现出显著疗效且具有可耐受的毒性水平，因此这种治疗晚期胃癌的创新方法已获得广泛关注。本文综述了晚期胃癌免疫治疗的最新进展，涵盖免疫检查点抑制剂、癌症疫苗、血管内皮生长因子-A抑制剂以及嵌合抗原受体T细胞疗法。当前研究重点在于分析临床应用的免疫治疗策略，探讨现有疗法面临的挑战，并探索突破其局限性的潜在解决方案。
肿瘤(癌症)患者之家